The NSAID sulindac has been successfully used alone or in combination with other agents to suppress colon tumorigenesis in patients with genetic predisposition and also showed its efficacy in prevention of sporadic colon adenomas. At the same time, some experimental and clinical reports suggest that a mutant oncogene may negate sulindac antitumor efficacy. To directly assess sulindac activity at suppressing premalignant lesions carrying K-RAS mutation, we utilized a novel mouse model with an inducible colon-specific expression of the mutant oncogene ( ). Tumor development and treatment effects were monitored by minimally invasive endoscopic Optical coherence tomography. Expression of the mutant allele accelerated azoxymethane (AOM)-induced colon carcinogenesis in C57BL/6 mice, a strain otherwise resistant to this carcinogen. Sulindac completely prevented AOM-induced tumor formation in wild-type ( wt) animals. In -mutant mice, a 38% reduction in tumor number, an 83% reduction in tumor volume ( ≤ 0.01) and an increase in the number of adenoma-free mice ( = 0.04) were observed. The partial response of animals to sulindac treatment was evident by the decrease in mucosal thickness ( < 0.01) and delay in progression of the precancerous aberrant crypt foci to adenomas. Molecular analyses showed significant induction in cyclooxygenase 2 (COX-2), cleaved caspase-3 (CC3), and Ki-67 expression by AOM, but not sulindac treatment, in all genotypes. Our data underscore the importance of screening for mutations in individuals with colon polyps to provide more personalized interventions targeting mutant signaling pathways. .
<p>Supplementary Table 1. Statistical analysis of endpoints derived from histology. Number of animals in different groups is listed in Figure 1B. Supplementary Table 2. Statistical analysis of adenoma grade by genotypes in the subset of AOM-induced mice, 34 weeks of age, from Table 1B. Number of slides analysed is presented in parentheses. Supplementary Table 3. Analysis of colon ACF by genotypes and treatment. Supplementary Figure 1. Comformation of colon-specific expression of mutant K-Ras allele in the compound Vil-Cre-ERT2K-rasG12D mouse. Supplementary Figure 2. Characterization downstream targets of mutant K-RAS in Vil-Cre-ERT2K-rasG12D mouse model by Western blot analysis in the colon tissue of Control and AOM-treated mice of different genotypes at 26 weeks of age (18 weeks after the last AOM injection when applicable).</p>
<p>Supplementary Table 1. Statistical analysis of endpoints derived from histology. Number of animals in different groups is listed in Figure 1B. Supplementary Table 2. Statistical analysis of adenoma grade by genotypes in the subset of AOM-induced mice, 34 weeks of age, from Table 1B. Number of slides analysed is presented in parentheses. Supplementary Table 3. Analysis of colon ACF by genotypes and treatment. Supplementary Figure 1. Comformation of colon-specific expression of mutant K-Ras allele in the compound Vil-Cre-ERT2K-rasG12D mouse. Supplementary Figure 2. Characterization downstream targets of mutant K-RAS in Vil-Cre-ERT2K-rasG12D mouse model by Western blot analysis in the colon tissue of Control and AOM-treated mice of different genotypes at 26 weeks of age (18 weeks after the last AOM injection when applicable).</p>
<div>Abstract<p>The NSAID sulindac has been successfully used alone or in combination with other agents to suppress colon tumorigenesis in patients with genetic predisposition and also showed its efficacy in prevention of sporadic colon adenomas. At the same time, some experimental and clinical reports suggest that a mutant <i>K-RAS</i> oncogene may negate sulindac antitumor efficacy. To directly assess sulindac activity at suppressing premalignant lesions carrying K-RAS mutation, we utilized a novel mouse model with an inducible colon-specific expression of the mutant <i>K-ras</i> oncogene (<i>K-ras<sup>G12D</sup></i>). Tumor development and treatment effects were monitored by minimally invasive endoscopic Optical coherence tomography. Expression of the mutant <i>K-ras</i> allele accelerated azoxymethane (AOM)-induced colon carcinogenesis in C57BL/6 mice, a strain otherwise resistant to this carcinogen. Sulindac completely prevented AOM-induced tumor formation in <i>K-ras</i> wild-type (<i>K-ras</i> wt) animals. In <i>K-ras<sup>G12D</sup></i>–mutant mice, a 38% reduction in tumor number, an 83% reduction in tumor volume (<i>P</i> ≤ 0.01) and an increase in the number of adenoma-free mice (<i>P</i> = 0.04) were observed. The partial response of <i>K-Ras<sup>G12D</sup></i> animals to sulindac treatment was evident by the decrease in mucosal thickness (<i>P</i> < 0.01) and delay in progression of the precancerous aberrant crypt foci to adenomas. Molecular analyses showed significant induction in cyclooxygenase 2 (COX-2), cleaved caspase-3 (CC3), and Ki-67 expression by AOM, but not sulindac treatment, in all genotypes. Our data underscore the importance of screening for <i>K-RAS</i> mutations in individuals with colon polyps to provide more personalized interventions targeting mutant <i>K-RAS</i> signaling pathways. <i>Cancer Prev Res; 11(1); 16–26. ©2017 AACR</i>.</p></div>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.